Your Voice In Europe: ROADMAP feedback for Evaluation of Union legislation on blood, tissues and cells

User's data:

- Domain: Public authority
- Name: David Olszowka
- Email: david.olszowka@mhra.gsi.gov.uk
- Country: United Kingdom
- Organisation: Medicines and Healthcare products Regulatory Agency
- Headquarter: select
- Size: select
- Scope: National
- Publication: can be published with your personal information

Related document: Evaluation of Union legislation on blood, tissues and cells

Feedback:

The UK Competent Authority for Blood and Blood Components, the MHRA, welcomes the Commission’s proposed roadmap for a comprehensive assessment of the Union legislation on blood and tissues and cells - Directives 2002/98/EC and 2004/23/EC in such an open, inclusive and transparent way.

Under section C.2. of the roadmap the UK proposes that the evaluation should also seek to provide clarity in relation to:

- The handling of borderline products e.g. Platelet Rich Fibrin (PRF), Platelet Rich Plasma (PRP) and serum eye drops;
- Continuity of supply in event of major disease outbreak e.g. pandemic flu;
- The basis for technical assessment of efficacy in more complex and innovative EU Tissue and Cells Directive (EUTCD) and EU Blood Directive (EUBD) products;
- Coverage of gaps in the transition of blood and tissues and cells into human medicines / Advances Therapy Medicinal Products (ATMPs) e.g. the period of cell derivation of embryonic stem cells and induced pluripotent stem cells and
- Risk-based deferral periods for donors at risk of blood-borne infections which are based on current evidence and regional epidemiology, for example, endoscopy and tattoos.